Premium
Efficacy of adapalene/benzoyl peroxide combination in moderate inflammatory acne and its impact on patient adherence
Author(s) -
Gollnick Harald P. M.,
Funke Gisela,
Kors Christian,
Titzmann Thomas,
Jöstingmeyer Petra,
Jäckel Andreas
Publication year - 2015
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/ddg.12613
Subject(s) - adapalene , medicine , acne , benzoyl peroxide , dermatology , regimen , observational study , adverse effect , chemistry , organic chemistry , polymerization , polymer
Summary Background and objectives Adapalene 0.1 %/benzoyl peroxide (BPO) 2.5 % (Epiduo®) is the first, fixed‐dose topical combination gel developed for the once‐daily treatment of acne. The objective of this observational study was to assess efficacy and patient adherence under daily clinical practice conditions in a large population of young adults and adolescents (12 to 20 years) with moderate inflammatory acne. Patients and methods A total of 2 780 patients receiving adapalene‐BPO were evaluated in this multicenter, open‐label, prospective non‐interventional observational study. Observation time per patient was approximately 12 weeks. Assessment parameters included changes in acne severity, treatment success, safety, and therapeutic adherence. Results After 12 weeks, the majority of patients (91.5 %) showed improvement of acne under adapalene‐BPO treatment, with an initial therapeutic response noted after a median time of 14 days. Overall, 21.8 % of participants displayed complete resolution of visible acne lesions. Treatment adherence was assessed as good in 63.2 % of patients. The majority of individuals (69.5 %) experienced no or only mild local skin irritations. No serious adverse drug reactions (ADR) were reported during the course of the study. Conclusions Adapalene‐BPO is effective and safe in the treatment of moderate inflammatory acne. The fixed‐dose combination and easy application simplifies the therapeutic regimen, leading to good treatment adherence in the majority of patients.